Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Transcode Therapeutics Inc (RNAZ)

Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,618
  • Shares Outstanding, K 696
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,550 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -3.21
  • Number of Estimates 1
  • High Estimate -3.21
  • Low Estimate -3.21
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +17.13%
on 12/18/24
15.13 -75.15%
on 11/26/24
-7.33 (-66.11%)
since 11/20/24
3-Month
3.21 +17.13%
on 12/18/24
26.40 -85.76%
on 10/11/24
-7.83 (-67.55%)
since 09/20/24
52-Week
3.21 +17.13%
on 12/18/24
264.00 -98.58%
on 12/26/23
-200.71 (-98.16%)
since 12/20/23

Most Recent Stories

More News
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split Effective December 4, 2024

TransCode Therapeutics will implement a 1-for-33 reverse stock split effective December 4, 2024, to maintain Nasdaq listing requirements.Quiver AI SummaryTransCode Therapeutics, Inc. announced a 1-for-33...

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics, Inc. Announces $8 Million Private Placement Agreement with Institutional Investors

TransCode Therapeutics announces an $8 million private placement of common stock and warrants for general corporate purposes.Quiver AI SummaryTransCode Therapeutics, Inc. has announced a securities purchase...

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics, Inc. Announces $8 Million Private Placement

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Approves 1-for-33 Reverse Stock Split to Maintain Nasdaq Listing

TransCode Therapeutics announces a 1-for-33 reverse stock split to meet Nasdaq listing requirements, effective date forthcoming.Quiver AI SummaryTransCode Therapeutics, Inc. has announced a 1-for-33 reverse...

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Open Letter to Shareholders

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

RNAZ : 3.76 (-2.34%)
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

RNAZ : 3.76 (-2.34%)

Business Summary

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 4.03
1st Resistance Point 3.90
Last Price 3.76
1st Support Level 3.65
2nd Support Level 3.53
3rd Support Level 3.40

See More

52-Week High 264.00
Fibonacci 61.8% 164.38
Fibonacci 50% 133.60
Fibonacci 38.2% 102.83
Last Price 3.76
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar